NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for all antiviral drug developments from the R&D firm TheraCour Pharma, Inc. ("TheraCour").
NanoViricides CEO talks lead drug asset's potential as MPOX therapy - ICYMI
NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Proactive to discuss the promise of its lead drug NV-387 as a broad-spectrum antiviral. Diwan explained that NV-387, a host mimetic drug, works differently from traditional antiviral treatments by mimicking a natural cellular feature, making it difficult for viruses to escape.
NanoViricides exploring emergency protocol to evaluate NV-387 for MPOX
NanoViricides (NYSE-A:NNVC) announced that it is investigating the potential use of its lead drug candidate NV-387 to treat MPOX patients under the World Health Organization's Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) protocol. This follows the organization's recent declaration of a Public Health Emergency due to the 2024 MPOX outbreak.
NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387
NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387, the company announced Monday. The drug candidate NV-387, which has shown promise in treating various viral infections including RSV, COVID-19, and Influenza in animal studies, could revolutionize the treatment of respiratory viruses, according to the company.
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program activities. Dr. Anil Diwan, the Company's President, and Executive Chairman, is currently visiting with various expert professionals with the objective of developing a Phase II clinical trial plan and corresponding clinical protocol for a Phase II clinical trial of the drug candidate NV-387.
NanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387
NanoViricides (NYSE-A:NNVC) has highlighted significant progress made in advancing its lead drug candidate NV-387 during the 2024 fiscal year 2024, which ended June 30, in a letter to investors. NV-387 is designed to disable viruses by mimicking the host cell, targeting a wide range of viruses including Influenza, COVID, RSV, and more.
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program and strategy in this letter to investors. NanoViricides is developing a unique direct-acting antiviral drug that mimics the host cell and thereby is designed to disable the virus particle from infecting the cell.
NanoViricides' lead asset for broad spectrum efficacy wins praise in industry reports
NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential of its broad spectrum drug candidate NV-387 as a viral therapy. In a research note titled “NNVC: NanoViricides (NYSE-A:NNVC) Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy,” author Dr David Bautz of ZacksSCR described the antiviral asset NV-387 as “exciting.
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separate and independent research reports have been published by industry analysts on the Company. "NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy," is the title of a new research note published by David Bautz, PhD, Zacks SCR, on July 31st, 2024.
NanoViricides spotlights lead drug candidate's potential as COVID therapy
NanoViricides (NYSE-A:NNVC) has highlighted the strong safety and efficacy of its lead clinical drug candidate NV-387 against coronaviruses. Animal studies of NV-387 have shown it can be “highly effective” in treating COVID infections.
NanoViricides discusses lead program and next steps
NanoViricides (NYSE-A:NNVC), a leader in broad-spectrum antiviral nanomedicines, is advancing its development program for NV-387. This single drug has shown activity against various respiratory viral infections in animal models.
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development program for NV-387, a single drug that has shown activity against many respiratory viral infections in animal models, enabling human clinical trials for a number of indications. There are several viruses that continue to cause epidemics in humans; seasonal epidemics with Influenza, RSV, and SARS-CoV-2 (COVID) are occurring every year.
